Current controversies and challenges in allergic rhinitis management

David Price, Pete Smith, Peter Hellings, Nikos Papadopoulos, Wytske Fokkens, Antonella Muraro, Ruth Murray, Alison Chisholm, Pascal Demoly, Glenis Scadding, Joaquim Mullol, Phil Lieberman, Claus Bachert, Ralph Mösges, Dermot Ryan, Jean Bousquet

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


There are many obstacles in the path of effective allergy management, in general, and allergic rhinitis (AR) control, in particular. Chief among them are: insufficient symptom relief in some patients provided by some currently considered first-line AR treatments in real life; an over-reliance on randomized controlled trials to direct AR guideline recommendations; the need for a broader interpretation of the AR evidence base (to include randomized controlled trials and real-life studies); poorly designed and interpreted studies; and lack of an AR control concept and common language of control. These controversies are fully reviewed here and challenging solutions have been presented.

Original languageEnglish
Pages (from-to)1205-1217
Number of pages13
JournalExpert Review of Clinical Immunology
Issue number11
Early online date29 Aug 2015
Publication statusPublished - 1 Sept 2015


  • allergic rhinitis
  • clinical relevance
  • control
  • guidelines
  • randomized controlled trials
  • real life


Dive into the research topics of 'Current controversies and challenges in allergic rhinitis management'. Together they form a unique fingerprint.

Cite this